ABL Diagnostics: Revenue up 90% in first half of 2026
In six months, ABL Diagnostics achieved 77.9% of the full-year 2025 revenue and its half-year net income exceeded by 29.7% that recorded over the twelve months of 2025. The molecular diagnostics company listed on Euronext Paris highlighted the acceleration of its growth drivers integrated since 2025 and maintains at this stage its annual revenue target of €12.265 million for 2026.
Revenue of €5.415 million and EBITDA margin of 24.3%
ABL Diagnostics' revenue reached €5.415 million in the first half of 2026, compared to €2.849 million in the first half of 2025, representing an increase of €2.566 million and published growth of 90.0%. The company indicates that this growth stems from the combination of its historical sequencing genotyping activities, its software solutions (DeepChek, ViroScore, MicrobioChek and NADIS), the acceleration of the UltraGene range (formerly Fast Track Diagnostics), the distribution activity of Vela Diagnostics solutions and the products and services distributed on behalf of CDL Pharma. In terms of results, EBITDA stood at €1.315 million in the first half of 2026, compared to €0.295 million a year earlier, representing growth of 346.5%. The EBITDA margin came in at 24.3% of revenue, compared to 10.34% in the first half of 2025, an improvement of 14.0 percentage points.
Shift to positive operating income of €1.115 million
Operating income, or EBIT, reached €1.115 million in the first half of 2026, compared to an operating loss of €0.066 million in the first half of 2025, an improvement of €1.181 million. Net income stood at €1.280 million, compared to €0.289 million a year earlier, up 343.4%. It exceeded by €293 thousand, or 29.7%, the net income of €987 thousand recorded over the full 2025 fiscal year. The company reported available cash of €853 thousand as of June 30, 2026, compared to €1.316 million as of December 31, 2025, a decrease of €463 thousand or 35.2%. It indicates that this change should be assessed in light of working capital movements, investments made during the half-year, the collection schedule for customer and tax receivables and financing movements that occurred during the period. It specifies having transferred to its equity €165 thousand in intangible assets and €60 thousand in tangible assets, as well as inventory acquired for a flat amount of €30 thousand, in support of the asset and activity takeover offer for Texcell France presented to the Commercial Court of Évry.
Annual target of €12.265 million maintained, 44.2% achieved as of June 30
ABL Diagnostics maintains at this stage its revenue target of €12.265 million for fiscal year 2026, published on June 1, 2026, which corresponds to targeted annual growth of 76.5% compared to €6.950 million in 2025. First-half revenue represents 44.2% of this target, leaving a balance of €6.850 million to be achieved in the second half. The roadmap includes annual targets of €1.582 million for UltraGene, €3.906 million for HIV activity, €1.565 million for Vela Diagnostics and €2.482 million for CDL Pharma. Since July 21, 2026, the company has integrated the assets of Texcell France acquired at the Commercial Court of Évry in the course of a judicial reorganization procedure, an operation that was accompanied by the integration of 29 new employees. The company indicates that it will update its 2026 revenue target to incorporate the revenues and costs associated with these assets.
